IL-6 levels in severe COVID-19 patients are significantly higher than in other patients, prompting several researchers to recommend TCZ to inhibit IL-6 signaling in patients with severe COVID-19 to improve patient symptoms (35, 87). The gene discussed is IL6; the disease is COVID-19.